RxCelerate have established expertise in the development, validation and use of LC-MS/MS assays.

The platform used is a Waters® Xevo® TQ-XS Triple Quadrupole Mass Spectrometer coupled to a Waters Acquity UPLC® I-Class system. The combination of a fast scanning mass spectrometer with an Ultra High Performance Liquid Chromatography (UHPLC) separation system allows rapid high resolution separations without compromising detection.

Matrices previously quantitated by RxCelerate include, but are not limited to, urine, plasma, tissue (brain, tumour, liver spleen), cells, cell media, cerebral spinal fluid, solutions and formulations. A variety of analytes, both small molecules and biologicals, can be quantified by LC-MS/MS, the analyses of which can be used for pharmacokinetic, pharmacodynamic or toxicological applications.

RxCelerate is GxP accredited by the MHRA and as such has the capability to provide GLP compliant bioanalysis to support not only research applications but regulated preclinical and Clinical studies.